Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:APVO NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.42-1.6%$2.82$7.96▼$24.15$12.20M0.6315,511 shs203,569 shsAPVOAptevo Therapeutics$3.03+1.7%$4.46$2.81▼$405.52$2.25M5.58613,104 shs198,444 shsNERVMinerva Neurosciences$2.03+1.8%$1.69$1.15▼$3.38$13.92M-0.3422,908 shs7,299 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+2.50%-3.53%-7.87%-64.81%-86.77%APVOAptevo Therapeutics-1.65%-1.00%+5.67%-82.71%-99.98%NERVMinerva Neurosciences-5.46%+18.81%+8.15%+24.38%-40.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AAPVOAptevo Therapeutics2.3999 of 5 stars3.52.00.00.02.70.01.3NERVMinerva Neurosciences4.2466 of 5 stars3.05.00.04.62.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AAPVOAptevo Therapeutics 3.00Buy$219,040.007,228,942.90% UpsideNERVMinerva Neurosciences 2.00Hold$5.00146.91% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AAPVOAptevo Therapeutics$3.11M0.74N/AN/A$65.21 per share0.05NERVMinerva NeurosciencesN/AN/A$0.20 per share10.07($3.67) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)APVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)NERVMinerva Neurosciences$1.44M$0.822.47N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)Latest APVO, NERV, and ALVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025N/AAPVOAptevo Therapeutics-$83.20N/AN/AN/AN/AN/A8/5/2025Q2 2025NERVMinerva Neurosciences-$0.95N/AN/AN/AN/AN/A5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78APVOAptevo TherapeuticsN/A0.670.67NERVMinerva NeurosciencesN/A9.219.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%APVOAptevo Therapeutics8.06%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%APVOAptevo Therapeutics0.01%NERVMinerva Neurosciences8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableAPVOAptevo Therapeutics50760,000756,000Not OptionableNERVMinerva Neurosciences9N/AN/ANot OptionableAPVO, NERV, and ALVR HeadlinesRecent News About These CompaniesChandigarh: Minerva enter knockout stage of Gothia Cup 2025July 17 at 8:15 AM | msn.comMinerva CEO navigates 'nightmare' lab market to secure new HQ in WoburnJuly 16 at 6:03 AM | bizjournals.comMinerva University Named World's Most Innovative University for Fourth Consecutive YearJuly 15 at 9:50 AM | uk.finance.yahoo.comFree concert on Minerva’s Municipal Park StageJuly 14, 2025 | morningjournalnews.comMHelsinki Cup: Minerva Academy in Round-16 with thumping 7-0 winJuly 14, 2025 | msn.comMinerva narrowly fell short in final, but won hearts with historic Helsinki Cup campaignJuly 13, 2025 | english.newsnationtv.comEMinerva Academy FC: Defying Odds and Dazzling Europe in Helsinki Cup-2025July 13, 2025 | devdiscourse.comDHelsinki Cup: Minerva Academy in semi-finals, two Finland clubs eliminatedJuly 12, 2025 | english.newsnationtv.comEMinerva Neurosciences Inc. (NERV) Stock Price Today - WSJJuly 11, 2025 | wsj.comMinerva registers fourth win in Helsinki CupJuly 10, 2025 | msn.comHelsinki Cup: Minerva Academy logs twin victoriesJuly 10, 2025 | msn.comMinerva Academy FC's Triumph: An Unstoppable Force in Helsinki Cup 2025July 10, 2025 | devdiscourse.comDHelsinki Cup: Minerva registered its fourth win, creating history by winning the match 9-0July 10, 2025 | news.webindia123.comNMinerva High School Athletic Hall of Fame announces Class of 2025 membersJuly 10, 2025 | msn.comValCUN installs Minerva metal Additive Manufacturing machine at Johns Hopkins UniversityJuly 8, 2025 | metal-am.comMMinerva Avenue Charting Next Steps Following Sudden FireJuly 8, 2025 | msn.comFire destroys popular North Nashville nightclub Minerva AvenueJuly 6, 2025 | msn.comMinerva nights event to include music, food, gamesJune 27, 2025 | cantonrep.comCNordic Capital invests in CRO and CDMO Minerva ImagingJune 11, 2025 | pehub.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, NERV, and ALVR Company DescriptionsAlloVir NASDAQ:ALVR$2.42 -0.04 (-1.63%) As of 07/17/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Aptevo Therapeutics NASDAQ:APVO$3.03 +0.05 (+1.68%) Closing price 04:00 PM EasternExtended Trading$3.03 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Minerva Neurosciences NASDAQ:NERV$2.02 +0.04 (+1.76%) Closing price 03:49 PM EasternExtended Trading$2.01 -0.02 (-0.74%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
